Tianyin Pharmaceutical Co. Inc. ( TPI) F2Q2011 Earnings Call February 15, 2011 9:00 AM ET Executives James Jiayuan Tong – CFO, Chief Business & Development Officer Jiang Guoqing – Chairman and CEO Analysts Adam Waldo [ph] – Lismore Partners [ph] Mark McLachlan [ph] – Mainstream Investment Advisers Angel Liu – Pope Asset Management Saul Rosenthal [ph] – Private Investor Boyd Hinds – Equinox Capital PresentationOperator
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Tianyin Pharmaceutical Incorporated Second Quarter Earnings Conference Call. (Operator Instructions). And at this time, I would now like to turn the conference over to Dr. James Tong, who’s Chief Financial Officer and Chief Business Development Officer. Please go ahead. James Jiayuan Tong Thank you, operator. Good morning. Good evening. Ladies and gentlemen, welcome to Tianyin Pharmaceutical TPI Second Quarter Fiscal Year 2011 Earnings Conference Call. I am James Jiayuan Tong, Chief Financial Officer and Chief Business and Development Officer at TPI along with Dr. Jiang Guoqing, Chief Executive Officer and Chairman of the company; and Simon Min Ren, Director of Investor Relations; and May Yenyuhan [ph], Assistant to CFO. During this conference call, we will be reviewing the second quarter fiscal year 2011 financial highlights followed by the question and answer period. Before we continue, please not that this call will contain forward-looking statements made under the Safe Harbor provisions of the US Private Security Litigation Reform Act of 1995. Any statements set forth in this presentation, that are not historical facts or forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include but are not limited to such factors as unanticipated changes in the product demand, increased competition, failure to obtain or maintain intellectual property protection, fluctuation in the economy, results of research and development, failure to obtain regulatory approvals and other information detailed from time to time in TPI’s filing and future filings with the United States Securities and Exchange Commission.